MA43021A - Nouveaux dérivés pyrrolo [2,3-d]pyrimidine utilisés en tant qu'inhibiteurs doubles de dyrk1/clk1 - Google Patents

Nouveaux dérivés pyrrolo [2,3-d]pyrimidine utilisés en tant qu'inhibiteurs doubles de dyrk1/clk1

Info

Publication number: MA43021A
Authority: MA; Morocco
Prior art keywords: dyrk1; clk1; pyrrolo; new derivatives; dual inhibitors
Prior art date: 2015-09-30

Application number

MA043021A

Other languages

English (en)

Inventor

Michaël Frank Burbridge

Francisco Humberto Cruzalegui

Andrea Fiumana

Nicolas Foloppe

András Kotschy

Stuart Ray

David Walmsley

Original Assignee

Servier Lab

Vernalis R&D Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-09-30

Filing date

2016-09-30

Publication date

2018-08-08

2016-09-30 Application filed by Servier Lab, Vernalis R&D Ltd filed Critical Servier Lab

2018-08-08 Publication of MA43021A publication Critical patent/MA43021A/fr

Links

JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 title 1
102100040862 Dual specificity protein kinase CLK1 Human genes 0.000 title 1
102100028554 Dual specificity tyrosine-phosphorylation-regulated kinase 1A Human genes 0.000 title 1
101000749294 Homo sapiens Dual specificity protein kinase CLK1 Proteins 0.000 title 1
101000838016 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 1A Proteins 0.000 title 1
230000009977 dual effect Effects 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MA043021A 2015-09-30 2016-09-30 Nouveaux dérivés pyrrolo [2,3-d]pyrimidine utilisés en tant qu'inhibiteurs doubles de dyrk1/clk1 MA43021A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR1559259A FR3041640B1 (fr)	2015-09-30	2015-09-30	NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT

Publications (1)

Publication Number	Publication Date
MA43021A true MA43021A (fr)	2018-08-08

Family

ID=54979756

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA043021A MA43021A (fr)	2015-09-30	2016-09-30	Nouveaux dérivés pyrrolo [2,3-d]pyrimidine utilisés en tant qu'inhibiteurs doubles de dyrk1/clk1

Country Status (26)

Country	Link
US (1)	US20180273538A1 (fr)
EP (1)	EP3356364A1 (fr)
JP (1)	JP2018533552A (fr)
KR (1)	KR20180054856A (fr)
CN (1)	CN108137582A (fr)
AU (1)	AU2016333508A1 (fr)
BR (1)	BR112018005851A2 (fr)
CA (1)	CA2999937A1 (fr)
CL (1)	CL2018000786A1 (fr)
CO (1)	CO2018003466A2 (fr)
CR (1)	CR20180176A (fr)
CU (1)	CU20180027A7 (fr)
DO (1)	DOP2018000082A (fr)
EA (1)	EA201890820A1 (fr)
EC (1)	ECSP18023286A (fr)
FR (1)	FR3041640B1 (fr)
HK (1)	HK1255467A1 (fr)
IL (1)	IL258231A (fr)
MA (1)	MA43021A (fr)
MX (1)	MX2018003861A (fr)
NI (1)	NI201800042A (fr)
PE (1)	PE20190337A1 (fr)
PH (1)	PH12018500605A1 (fr)
SV (1)	SV2018005656A (fr)
TN (1)	TN2018000087A1 (fr)
WO (1)	WO2017055533A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20190043437A (ko)	2017-10-18	2019-04-26	씨제이헬스케어 주식회사	단백질 키나제 억제제로서의 헤테로고리 화합물
KR102054910B1 (ko) *	2017-12-19	2019-12-12	한림제약(주)	피롤로[2,3-d]피리미딘 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
US12528810B2 (en)	2018-03-01	2026-01-20	Arizona Board Of Regents On Behalf Of The University Of Arizona	Small molecule inhibitors of DYRK/CLK and uses thereof
CN113164476A (zh) *	2018-09-28	2021-07-23	代表亚利桑那大学的亚利桑那校董会	Dyrk1/clk的小分子抑制剂及其用途
FI3873903T3 (fi)	2018-10-31	2024-03-26	Gilead Sciences Inc	Substituoituja 6-azabentsiimidatsoliyhdisteitä HPK1-inhibiittoreina
KR102658602B1 (ko)	2018-10-31	2024-04-19	길리애드 사이언시즈, 인코포레이티드	Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물
KR102195348B1 (ko)	2018-11-15	2020-12-24	에이치케이이노엔 주식회사	단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
TWI826690B (zh)	2019-05-23	2023-12-21	美商基利科學股份有限公司	經取代之烯吲哚酮化物及其用途
CN110407744A (zh) *	2019-08-13	2019-11-05	上海毕得医药科技有限公司	一种1-(4-氨基吡啶-2-基)乙酮的合成方法
AR120799A1 (es) *	2019-12-20	2022-03-16	Hoffmann La Roche	2-[4-cloro-6-[2-[4-[[4-(hidroximetil)-1-piperidil]metil]fenil]etinil]-1-oxoisoindolin-2-il]-2-(6,7-dihidro-5h-pirrolo[1,2-c]imidazol-1-il)-n-tiazol-2-il-acetamida como inhibidor de egfr
WO2022117012A1 (fr) *	2020-12-02	2022-06-09	百极弘烨（广东）医药科技有限公司	Inhibiteur de jak spirocyclique, composition pharmaceutique le contenant, et son application
WO2022245776A1 (fr) *	2021-05-20	2022-11-24	Saint John's Cancer Institute	Inhibiteurs anti-cdk pour le traitement du cancer
WO2023064361A1 (fr) *	2021-10-12	2023-04-20	Biosplice Therapeutics, Inc.	7h-pyrrolo[2, 3-d]pyrimidines et leur préparation et leurs utilisations
EP4415817A1 (fr) *	2021-10-12	2024-08-21	BioSplice Therapeutics, Inc.	1h-pyrrolo[2,3-b]pyridines en tant qu'inhibiteurs de dyrk1a
EP4415816B1 (fr)	2021-10-12	2026-03-18	BioSplice Therapeutics, Inc.	Dérivés de pyrrolo[2,1-f][1,2,4]triazines comme inhibiteurs de dyrk1a
WO2023110843A1 (fr) *	2021-12-15	2023-06-22	Almirall, S.A.	Dérivés hétérobicycliques utilisés comme inhibiteurs de l'itk
CN116621843B (zh) *	2022-06-13	2024-05-24	四川大学华西医院	一种dna甲基转移酶1抑制剂及其制备方法和用途
CN115785134B (zh) *	2022-10-28	2023-08-29	浙大城市学院	一种含氮杂环的硼酸化合物及制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ564283A (en)	2005-05-20	2011-07-29	Methylgene Inc	Inhibitors of VEGF receptor and HGF receptor signaling
AR056691A1 (es)	2005-10-13	2007-10-17	Glaxo Group Ltd	Derivados pirrolopirimidina como inhibidores de syk
BRPI0708779A2 (pt)	2006-03-11	2011-06-14	Vernalis R & D	derivados de pirrolopirimidina utilizados como inibidores de hsp90
FR2912744B1 (fr) *	2007-02-16	2012-09-07	Centre Nat Rech Scient	Composes pyrrolo°2,3-b!pyridine,composes azaindoles utiles dans la synthese de ces composes pyrrolo°2,3-b!pyridine, leurs procedes de fabrication et leurs utilisations.
AR070127A1 (es)	2008-01-11	2010-03-17	Novartis Ag	Pirrolo - pirimidinas y pirrolo -piridinas
CN105732639A (zh) *	2012-06-29	2016-07-06	辉瑞大药厂	作为LRRK2抑制剂的4-(取代的氨基)-7H-吡咯并〔2,3-d〕嘧啶类
EP3083618B1 (fr) *	2013-12-17	2018-02-21	Pfizer Inc	Nouvelles 1h-pyrrolo[2,3- b]pyridines 3,4-disubstituées et 7h-pyrrolo[2,3-c]pyridazines 4,5-disubstituées en tant qu'inhibiteurs de la lrrk2

2015
- 2015-09-30 FR FR1559259A patent/FR3041640B1/fr not_active Expired - Fee Related
2016
- 2016-09-30 CN CN201680058179.3A patent/CN108137582A/zh not_active Withdrawn
- 2016-09-30 CR CR20180176A patent/CR20180176A/es unknown
- 2016-09-30 MX MX2018003861A patent/MX2018003861A/es unknown
- 2016-09-30 WO PCT/EP2016/073403 patent/WO2017055533A1/fr not_active Ceased
- 2016-09-30 CA CA2999937A patent/CA2999937A1/fr not_active Abandoned
- 2016-09-30 JP JP2018516488A patent/JP2018533552A/ja active Pending
- 2016-09-30 BR BR112018005851A patent/BR112018005851A2/pt not_active Application Discontinuation
- 2016-09-30 EP EP16774684.1A patent/EP3356364A1/fr not_active Withdrawn
- 2016-09-30 AU AU2016333508A patent/AU2016333508A1/en not_active Abandoned
- 2016-09-30 TN TNP/2018/000087A patent/TN2018000087A1/en unknown
- 2016-09-30 HK HK18114640.5A patent/HK1255467A1/zh unknown
- 2016-09-30 EA EA201890820A patent/EA201890820A1/ru unknown
- 2016-09-30 US US15/763,626 patent/US20180273538A1/en not_active Abandoned
- 2016-09-30 PE PE2018000410A patent/PE20190337A1/es unknown
- 2016-09-30 MA MA043021A patent/MA43021A/fr unknown
- 2016-09-30 CU CUP2018000027A patent/CU20180027A7/xx unknown
- 2016-09-30 KR KR1020187012166A patent/KR20180054856A/ko not_active Withdrawn
2018
- 2018-03-19 IL IL258231A patent/IL258231A/en unknown
- 2018-03-20 PH PH12018500605A patent/PH12018500605A1/en unknown
- 2018-03-22 SV SV2018005656A patent/SV2018005656A/es unknown
- 2018-03-23 NI NI201800042A patent/NI201800042A/es unknown
- 2018-03-26 CL CL2018000786A patent/CL2018000786A1/es unknown
- 2018-03-26 EC ECIEPI201823286A patent/ECSP18023286A/es unknown
- 2018-03-26 DO DO2018000082A patent/DOP2018000082A/es unknown
- 2018-03-28 CO CONC2018/0003466A patent/CO2018003466A2/es unknown

Also Published As

Publication number	Publication date
HK1255467A1 (zh)	2019-08-16
JP2018533552A (ja)	2018-11-15
PH12018500605A1 (en)	2018-09-24
CL2018000786A1 (es)	2018-09-28
TN2018000087A1 (en)	2019-07-08
WO2017055533A1 (fr)	2017-04-06
IL258231A (en)	2018-05-31
KR20180054856A (ko)	2018-05-24
CO2018003466A2 (es)	2018-07-10
MX2018003861A (es)	2018-08-16
DOP2018000082A (es)	2018-10-15
EP3356364A1 (fr)	2018-08-08
CU20180027A7 (es)	2018-07-05
AU2016333508A1 (en)	2018-04-12
US20180273538A1 (en)	2018-09-27
ECSP18023286A (es)	2018-04-30
FR3041640A1 (fr)	2017-03-31
CR20180176A (es)	2018-05-31
CA2999937A1 (fr)	2017-04-06
NI201800042A (es)	2018-06-21
SV2018005656A (es)	2018-08-10
PE20190337A1 (es)	2019-03-07
BR112018005851A2 (pt)	2018-10-09
FR3041640B1 (fr)	2019-05-17
EA201890820A1 (ru)	2018-10-31
CN108137582A (zh)	2018-06-08

Publication	Publication Date	Title
MA43021A (fr)	2018-08-08	Nouveaux dérivés pyrrolo [2,3-d]pyrimidine utilisés en tant qu'inhibiteurs doubles de dyrk1/clk1
FR22C1006I2 (fr)	2023-01-27	Derives de pyrrolo-[2,3-d]pyrimidine en tant qu'inhibiteurs des janus kinases (jak)
MA52987A (fr)	2021-04-28	Dérivés de pyrazolo[1,5-a]pyrazin-4-yl en tant qu'inhibiteurs de jak
MA53675A (fr)	2021-11-17	Composés substitués de pyrazolo[1,5-a]pyridine en tant qu'inhibiteurs de la kinase ret
DK3322706T3 (da)	2021-02-01	Substituerede pyrazolo[1,5-a]pyridin-forbindelser som ret-kinaseinhibitorer
MA47125A (fr)	2021-04-28	Dérivés de pyrazole en tant qu'inhibiteurs de malt1
DK3808749T3 (da)	2023-06-06	Pyrazolo[1,5-a]pyrimidiner, der er nyttige som inhibitorer af atr-kinase til behandling af kræftsygdomme
DK3324977T3 (da)	2022-10-17	Benzodiazepinderivater som rsv-inhibitorer
DK3429591T3 (da)	2023-06-19	Substituerede thieno[2,3-D]pyrimidin-derivater som inhibitorer af Menin-MLL og fremgangsmåder til anvendelse
LT3555097T (lt)	2022-08-25	Imidazo[4,5-d]pirolo[2,3-b]piridino junginiai kaip janus kinazės inhibitoriai
SI3379933T1 (sl)	2023-07-31	Fungicidni sestavki, ki vsebujejo derivate 2,4-diokso-1,4-dihidrotieno (2,3-d)pirimidina
MA40774A (fr)	2017-08-08	Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
ZA201607736B (en)	2017-09-27	Analogs of 4h-pyrazolo[1,5-a]benzimidazole compounds as parp inhibitors
EP2863914A4 (fr)	2015-12-16	Dérivés de pyrazolyle en tant qu'inhibiteurs de syk
EP3231805A4 (fr)	2018-06-13	Sel de composé de pyrrolo[2,3-d]pyrimidine et nouveau polymorphe de sel
ME03672B (fr)	2020-10-20	1h-pyrazolo [4,3-b]pyridines en tant qu'inhibiteurs de pde1
MA43020A (fr)	2018-08-08	Nouveaux dérivés d'imidazo[4,5-b]pyridine utilisés comme inhibiteurs de dyrk1/clk1 doubles
EP3380475A4 (fr)	2019-07-03	Dérivés d'octahydropyrrolo [3, 4-c
EP3328840A4 (fr)	2019-02-20	Composés bicycliques triazolo substitués en tant qu'inhibiteurs de pde2
MA41542A (fr)	2021-04-14	Nouveaux dérivés de n-acyl-arylsulfonamide utilisés en tant qu'inhibiteurs d'aminoacyl-arnt synthétase
LT3325482T (lt)	2020-11-25	Citotoksinių benzodiazepino darinių paruošimo būdai
MA46690A (fr)	2019-09-11	Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2
EP3508487A4 (fr)	2020-03-18	COMPOSÉ DE PYRAZOLO [1,5-a]PYRIMIDINE
EA201690716A1 (ru)	2016-10-31	ПИРИДО[2,3-d]ПИРИМИДИН-4-ОНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ТАНКИРАЗЫ
EP3679042A4 (fr)	2021-01-13	Dérivés d'imidazo[1,5-a]pyrazine en tant qu'inhibiteurs de pi3kdelta